文献速递鼻科

RADA-16降低下鼻甲黏膜下切除术术后鼻出血

RADA-16 Reduces Postoperative Epistaxis After Inferior Turbinate Submucosal Resection.
PubMed 文献 · Laryngoscope · 2025-05-19

本回顾性研究纳入2020年1月至2024年3月由同一术者行下鼻甲黏膜下切除术(ITR)的985例患者,其中571例使用RADA-16、414例未使用。使用RADA-16组术后出血风险显著低于未使用组(OR 0.17,95%CI 0.036-0.808,p=0.026),但两组每例出血相关费用无显著差异(379.74美元 vs 436.21美元,p=0.36)。

要点

  • 使用RADA-16组术后出血风险显著低于未使用组(OR 0.17,95%CI 0.036-0.808)。
  • 使用RADA-16组出血相关费用为379.74美元,未使用组为436.21美元,差异无统计学意义(p=0.36)。
  • 未使用RADA-16组接受抗凝治疗的比例更高(p<0.001),但抗凝使用与出血事件无关联。

核心结论

  • 本研究发现接受RADA-16的患者在ITR术后发生鼻出血的可能性更低。

研究设计与样本

  • 回顾性研究,纳入2020年1月至2024年3月由同一术者行ITR手术的985例患者电子健康记录,其中571例接受RADA-16、414例未接受。

主要发现

  • 总体术后出血发生率为1.11%,RADA-16组为0.35%,非RADA-16组为2.17%。
  • 接受RADA-16的患者术后出血风险显著更低(OR 0.17,95%CI 0.036-0.808,p=0.026)。
  • 两组在额外鼻部手术或出血性疾病患病率方面无显著差异。
  • 非RADA-16组接受抗凝治疗的可能性更高(p<0.001),但未观察到抗凝药物使用与出血事件之间的关系。
  • 成本效益分析显示,RADA-16组每例患者出血相关费用为379.74美元,非RADA-16组为436.21美元(p=0.36)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: RADA-16 is a self-assembling peptide matrix with the ability to form a hydrogel structure, showing promise for improved wound healing and hemostasis. Our objective was to understand the utility of RADA-16 on postoperative bleeding rates following inferior turbinate submucosal resection (ITR) surgery. STUDY DESIGN: Retrospective study. METHODS: Electronic health records of patients who underwent ITR surgery with a single surgeon from January 2020 to March 2024 were reviewed. Univariate and multivariate analyses were performed to determine differences in postoperative epistaxis rates between RADA-16 and non-RADA-16 cohorts. Further analysis was performed to compare healthcare-associated costs. RESULTS: Our analysis included 985 patients who underwent ITR, of whom 571 received RADA-16 and 414 did not. Overall, 1.11% of patients experienced postoperative bleeding, 0.35% in the RADA-16 cohort and 2.17% in the non-RADA-16 cohort. Patients receiving RADA-16 had a significantly lower risk of postoperative hemorrhage (OR 0.17, 95% CI 0.036-0.808, p = 0.026). Comparison of the two cohorts showed no significant difference in the prevalence of additional nasal surgery or bleeding disorders. The non-RADA-16 group was more likely to be on anticoagulation treatment (p < 0.001); however, no relationship between anticoagulant usage and bleeding episodes was observed. After cost-effectiveness analysis, we found the bleeding cost per patient was $379.74 for the RADA-16 group and $436.21 for the non-RADA-16 group (p = 0.36). CONCLUSIONS: RADA-16 is believed to improve wound healing and hemostasis. In our study, we found that patients receiving RADA-16 are less likely to experience epistaxis following ITR surgery.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Xu A, Kwon E, Filipkowski A, et al. RADA-16 Reduces Postoperative Epistaxis After Inferior Turbinate Submucosal Resection. Laryngoscope. 2025. PMID: 40387278. doi:10.1002/lary.32278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。